104 / 1498
•
Long term side effects of chemo- and radiotherapy
•
Poor prognosis of patients with relapse or refractory disease
•
Small amount of malignant cells (Hodgkin)
•
Residual dormant cells lead to relapse
•
Good target antigens (CD20, CD30, others)
•
Lymphoma well vascularized
Rationale for immunotherapy of malignant lymphoma